|Systematic (IUPAC) name|
|CAS Registry Number|
|Molecular mass||537.564 g/mol|
|(what is this?)|
It is classified as reversible.
Mechanism of action
Ambenonium exerts its actions against myasthenia gravis by competitive reversible inhibition of acetylcholinesterase, the enzyme responsible for the hydrolysis of acetylcholine. Myasthenia gravis occurs when the body produces antibodies against acetylcholine receptors, and thus inhibits signal transmission across the myoneural junction. Ambenonium reversibly binds acetylcholinesterase, inactivates it and therefore increases levels of acetylcholine. This, in turn, facilitates transmission of impulses across the myoneural junction and effectively treats the disease.
Ambenonium is used to treat muscle weakness due to disease or defect of the neuromuscular junction (myasthenia gravis).
- Bolognesi ML, Cavalli A, Andrisano V et al. (September 2003). "Design, synthesis and biological evaluation of ambenonium derivatives as AChE inhibitors". Farmaco 58 (9): 917–28. doi:10.1016/S0014-827X(03)00150-2. PMID 13679187.
- Hodge AS, Humphrey DR, Rosenberry TL (May 1992). "Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities". Mol. Pharmacol. 41 (5): 937–42. PMID 1588924.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|